Research Papers:

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

Sheng Guo, Dawei Chen, Xuesong Huang, Jie Cai, Jean-Pierre Wery and Qi-Xiang Li _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:50575-50581. https://doi.org/10.18632/oncotarget.10499

Metrics: PDF 1562 views  |   HTML 2364 views  |   ?  


Sheng Guo1, Dawei Chen1, Xuesong Huang1, Jie Cai1, Jean-Pierre Wery1, Qi-Xiang Li1,2

1Division of Translational Oncology, Crown Bioscience, Inc., Santa Clara, CA 95054, USA

2State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China

Correspondence to:

Qi-Xiang Li, email: [email protected]

Keywords: PDX, Erbitux, expression signature, patient stratification, biomarker

Received: December 10, 2015     Accepted: June 29, 2016     Published: July 8, 2016


Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizing a cetuximab mouse clinical trial (MCT) dataset on a cohort of 25 randomly selected EGFR+ CRC patient-derived xenografts (PDXs). While we found that the expression of EGFR and its ligands are not predictive of the cetuximab response, we tested a published RAS pathway signature, a 147-gene expression signature proposed to describe RAS pathway activity, against this MCT dataset. Interestingly, our study showed that the observed cetuximab activity has a strong correlation with the RAS pathway signature score, which was also demonstrated to have a certain degree of correlation with a historic clinical dataset. Altogether, the independent validations in unrelated datasets from independent cohort of CRCs strongly suggest that RAS pathway signature may be a relevant expression signature predictive of CRC response to cetuximab. Our data seem to suggest that an mRNA expressing signature may also be developed as a predictive biomarker for drug response, similarly to genetic mutations.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10499